{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T16:56:07Z","timestamp":1790009767216,"version":"4.0.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Objectives<\/jats:title>\n                    <jats:p>Aspergillus and Candida spp. are important causes of systemic fungal infections. Although various therapies are available, resistance to current antifungal treatments, particularly azoles, is increasing. Combinations of antifungals can be used to treat infections with resistant pathogens. In a recent in vitro study, antagonism was reported in a single A. fumigatus isolate between olorofim and voriconazole. Available clinical data are limited but do not reflect this phenomenon. The in vitro interactions of olorofim with current antifungal agents (voriconazole, posaconazole, isavuconazole, fluconazole, amphotericin B, terbinafine and caspofungin) were evaluated against various Aspergillus and three Candida species.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In vitro interactions were evaluated by the EUCAST microdilution broth technique modified for checkerboard assay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Olorofim demonstrated different interaction patterns when tested in combination with various classes of antifungal. Unidirectional antagonism was seen between olorofim and the mould-active azoles with the strongest effect seen in A. niger: azole MIC values were unaffected but olorofim MIC values increased, although remained within wild-type distributions. Olorofim antagonized amphotericin B activity in the single A. niger strain tested. There was indifference between olorofim and fluconazole, terbinafine and caspofungin for all isolates. Finally, olorofim showed indifference with fluconazole or voriconazole against three Candida species.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Mould-active azoles antagonize olorofim activity against Aspergillus spp. combination MICs remain within wild-type distributions for Aspergillus spp., other than for A. niger. In addition, olorofim does not affect the anti-Candida effect of fluconazole and could be co-dosed where necessary without loss of the effect of the azole against the yeast.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf354","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T11:59:35Z","timestamp":1757073575000},"page":"3139-3149","source":"Crossref","is-referenced-by-count":10,"title":["<i>In vitro<\/i>\n                    evaluation of olorofim and antifungal combinations against\n                    <i>Aspergillus<\/i>\n                    and\n                    <i>Candida<\/i>\n                    species"],"prefix":"10.1093","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7294-3054","authenticated-orcid":false,"given":"Corinne","family":"Pinder","sequence":"first","affiliation":[{"name":"F2G Ltd , Alderley Park, Macclesfield, Cheshire SK10 4TF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ressa","family":"Lebedinec","sequence":"additional","affiliation":[{"name":"F2G Ltd , Alderley Park, Macclesfield, Cheshire SK10 4TF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason D","family":"Oliver","sequence":"additional","affiliation":[{"name":"F2G Ltd , Alderley Park, Macclesfield, Cheshire SK10 4TF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Birch","sequence":"additional","affiliation":[{"name":"F2G Ltd , Alderley Park, Macclesfield, Cheshire SK10 4TF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Law","sequence":"additional","affiliation":[{"name":"F2G Ltd , Alderley Park, Macclesfield, Cheshire SK10 4TF ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"2025110817254109800_dkaf354-B1","doi-asserted-by":"publisher","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect Dis"},{"key":"2025110817254109800_dkaf354-B2","author":"World Health Organization","year":"2022"},{"key":"2025110817254109800_dkaf354-B3","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of Aspergillosis: 2016 update by the Infectious Diseases Society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2025110817254109800_dkaf354-B4","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cmi.2018.01.002","article-title":"Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline","volume":"24","author":"Ullmann","year":"2018","journal-title":"Clin Microbiol Infect"},{"key":"2025110817254109800_dkaf354-B5","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41579-022-00720-1","article-title":"Tackling the emerging threat of antifungal resistance to human health","volume":"20","author":"Fisher","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"2025110817254109800_dkaf354-B6","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/s41564-022-01091-2","article-title":"Population genomics confirms acquisition of drug-resistant Aspergillus fumigatus infection by humans from the environment","volume":"7","author":"Rhodes","year":"2022","journal-title":"Nat Microbiol"},{"key":"2025110817254109800_dkaf354-B7","doi-asserted-by":"publisher","first-page":"eadh8839","DOI":"10.1126\/sciadv.adh8839","article-title":"Citizen science reveals landscape-scale exposures to multiazole-resistant Aspergillus fumigatus bioaerosols","volume":"9","author":"Shelton","year":"2023","journal-title":"Sci Adv"},{"key":"2025110817254109800_dkaf354-B8","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.medmal.2019.07.014","article-title":"Azole-resistant Aspergillus fumigatus: a global phenomenon originating in the environment?","volume":"50","author":"Jeanvoine","year":"2020","journal-title":"Med Mal Infect"},{"key":"2025110817254109800_dkaf354-B9","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.3201\/eid2911.230984","article-title":"Refractory Microascus bronchopulmonary infection treated with olorofim, France","volume":"29","author":"Faure","year":"2023","journal-title":"Emerg Infect Dis"},{"key":"2025110817254109800_dkaf354-B10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1128\/CMR.00039-07","article-title":"Infections caused by Scedosporium spp","volume":"21","author":"Cortez","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"2025110817254109800_dkaf354-B11","doi-asserted-by":"publisher","first-page":"8271471","DOI":"10.1155\/2020\/8271471","article-title":"Eradication of Lomentospora prolificans osteomyelitis of the wrist with combination antifungal therapy, voriconazole bone cement, and surgical debridement","volume":"2020","author":"Lee","year":"2020","journal-title":"Case Rep Orthop"},{"key":"2025110817254109800_dkaf354-B12","doi-asserted-by":"publisher","first-page":"12809","DOI":"10.1073\/pnas.1608304113","article-title":"F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase","volume":"113","author":"Oliver","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2025110817254109800_dkaf354-B13","doi-asserted-by":"publisher","first-page":"e00129-19","DOI":"10.1128\/AAC.00129-19","article-title":"Efficacy of olorofim (F901318) against Aspergillus fumigatus, A. nidulans, and A. tanneri in murine models of profound neutropenia and chronic granulomatous disease","volume":"63","author":"Seyedmousavi","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817254109800_dkaf354-B14","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3390\/jof6030122","article-title":"Review of the novel investigational antifungal olorofim","volume":"6","author":"Wiederhold","year":"2020","journal-title":"J Fungi (Basel)"},{"key":"2025110817254109800_dkaf354-B15","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1093\/mmy\/myx161","article-title":"In vitro activity of the novel antifungal compound F901318 against Australian Scedosporium and Lomentospora fungi","volume":"56","author":"Biswas","year":"2018","journal-title":"Med Mycol"},{"key":"2025110817254109800_dkaf354-B16","doi-asserted-by":"publisher","first-page":"106105","DOI":"10.1016\/j.ijantimicag.2020.106105","article-title":"In vitro activity of olorofim (F901318) against fungi of the genus, Scedosporium and Rasamsonia as well as against Lomentospora prolificans, Exophiala dermatitidis and azole-resistant Aspergillus fumigatus","volume":"56","author":"Kirchhoff","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025110817254109800_dkaf354-B17","doi-asserted-by":"publisher","first-page":"2133","DOI":"10.1093\/jac\/dkaa157","article-title":"Antibiofilm activity of antifungal drugs, including the novel drug olorofim, against Lomentospora prolificans","volume":"75","author":"Kirchhoff","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025110817254109800_dkaf354-B18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1111\/myc.13548","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim has potent in vitro activity against Microascus\/Scopulariopsis, Rasamsonia, Penicillium and Talaromyces species","volume":"66","author":"Wiederhold","year":"2022","journal-title":"Mycoses"},{"key":"2025110817254109800_dkaf354-B19","doi-asserted-by":"publisher","first-page":"e0289441","DOI":"10.1371\/journal.pone.0289441","article-title":"Characterisation of putative class 1A DHODH-like proteins from mucorales and dematiaceous mould species","volume":"18","author":"Pinder","year":"2023","journal-title":"PLoS One"},{"key":"2025110817254109800_dkaf354-B20","doi-asserted-by":"publisher","first-page":"3068","DOI":"10.1093\/jac\/dky329","article-title":"Dihydroorotate dehydrogenase inhibitor olorofim exhibits promising activity against all clinically relevant species within Aspergillus section Terrei","volume":"73","author":"Lackner","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"2025110817254109800_dkaf354-B21","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.1093\/jac\/dkx177","article-title":"In vitro activity of the novel antifungal compound F901318 against difficult-to-treat Aspergillus isolates","volume":"72","author":"Buil","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"2025110817254109800_dkaf354-B22","doi-asserted-by":"publisher","first-page":"e01527-20","DOI":"10.1128\/AAC.01527-20","article-title":"Olorofim susceptibility testing of 1,423 Danish mold isolates obtained in 2018-2019 confirms uniform and broad-spectrum activity","volume":"65","author":"Astvad","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817254109800_dkaf354-B23","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/22221751.2022.2034485","article-title":"Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance","volume":"11","author":"Buil","year":"2022","journal-title":"Emerg Microbes Infect"},{"key":"2025110817254109800_dkaf354-B24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1473-30992500224-5","article-title":"Olorofim for the treatment of invasive fungal diseases in patients with few or no therapeutic options: a single-arm, open-label, phase 2b study","volume":"25","author":"Maertens","year":"2025","journal-title":"Lancet Infect Dis"},{"key":"2025110817254109800_dkaf354-B25","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1128\/AAC.48.3.693-715.2004","article-title":"Combination antifungal therapy","volume":"48","author":"Johnson","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817254109800_dkaf354-B26","doi-asserted-by":"publisher","first-page":"e0221522","DOI":"10.1128\/mbio.02215-22","article-title":"Antagonism of the azoles to olorofim and cross-resistance are governed by linked transcriptional networks in Aspergillus fumigatus","volume":"13","author":"van Rhijn","year":"2022","journal-title":"mBio"},{"key":"2025110817254109800_dkaf354-B27","author":"Guinea","year":"2022"},{"key":"2025110817254109800_dkaf354-B28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"2025110817254109800_dkaf354-B29","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1093\/jac\/dkz529","article-title":"Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim","volume":"75","author":"Lim","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025110817254109800_dkaf354-B30","article-title":"Outcomes of invasive fungal disease in a subgroup of patients receiving olorofim\/azole combination in an open label salvage study","author":"Zinzi","journal-title":"Trends in Medical Mycology, Athens, Greece, 2023"},{"key":"2025110817254109800_dkaf354-B31","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf355","article-title":"Antagonistic interaction between posaconazole and olorofim in a murine model of invasive pulmonary Aspergillosis","author":"Darlow","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2025110817254109800_dkaf354-B32","doi-asserted-by":"publisher","first-page":"e01157-17","DOI":"10.1128\/mBio.01157-17","article-title":"Pharmacodynamics of the orotomides against Aspergillus fumigatus: new opportunities for treatment of multidrug-resistant fungal disease","volume":"8","author":"Hope","year":"2017","journal-title":"mBio"},{"key":"2025110817254109800_dkaf354-B33","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2022"},{"key":"2025110817254109800_dkaf354-B34","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1007\/s11046-024-00871-0","article-title":"Insights from three pan-European multicentre studies on invasive Candida infections and outlook to ECMM Candida IV","volume":"189","author":"Wolfgruber","year":"2024","journal-title":"Mycopathologia"},{"key":"2025110817254109800_dkaf354-B35","author":"Guinea","year":"2023"},{"key":"2025110817254109800_dkaf354-B36","author":"CLSI","year":"2017"},{"key":"2025110817254109800_dkaf354-B37","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2023"},{"key":"2025110817254109800_dkaf354-B38","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2020"},{"key":"2025110817254109800_dkaf354-B39","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2020"},{"key":"2025110817254109800_dkaf354-B40","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1128\/AAC.48.6.2007-2013.2004","article-title":"In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models","volume":"48","author":"Te Dorsthorst","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817254109800_dkaf354-B41","doi-asserted-by":"publisher","first-page":"3582","DOI":"10.1093\/jac\/dkaa351","article-title":"In vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies","volume":"75","author":"Rivero-Menendez","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2025110817254109800_dkaf354-B42","doi-asserted-by":"publisher","first-page":"e0043421","DOI":"10.1128\/AAC.00434-21","article-title":"In vivo efficacy of olorofim against systemic scedosporiosis and lomentosporiosis","volume":"65","author":"Seyedmousavi","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"2025110817254109800_dkaf354-B43","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2020"},{"key":"2025110817254109800_dkaf354-B44","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2020"},{"key":"2025110817254109800_dkaf354-B45","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2024"},{"key":"2025110817254109800_dkaf354-B46","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/jof9080807","article-title":"The transcriptome response to azole compounds in Aspergillus fumigatus shows differential gene expression across pathways essential for azole resistance and cell survival","volume":"9","author":"Hokken","year":"2023","journal-title":"J Fungi (Basel)"},{"key":"2025110817254109800_dkaf354-B47","doi-asserted-by":"publisher","first-page":"e0000423","DOI":"10.1128\/cmr.00004-23","article-title":"Scedosporiosis and lomentosporiosis: modern perspectives on these difficult-to-treat rare mold infections","volume":"37","author":"Neoh","year":"2024","journal-title":"Clin Microbiol Rev"},{"key":"2025110817254109800_dkaf354-B48","author":"European Committee on Antimicrobial Susceptibility Testing","year":"2020"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/3139\/64432758\/dkaf354.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/11\/3139\/64432758\/dkaf354.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:25:47Z","timestamp":1762640747000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/11\/3139\/8268470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,9,30]]},"published-print":{"date-parts":[[2025,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf354","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,9,30]]}}}